Latest news with #Bonello
Yahoo
2 days ago
- Business
- Yahoo
Bertrand Bonello to Be Honored at Madrid's Second ECAM Forum Co-Pro Showcase (EXCLUSIVE)
Triple Palme d'Or nominated French filmmaker Bertrand Bonello ('Saint Laurent,' 'House of Tolerance,' 'Tiresia') whose latest daring work 'The Beast' was one of the hottest titles in the 2023 Venice competition, will be the guest of honor at the second ECAM Forum co-production platform, which will unspool over June 10-13 in Madrid. On the heels of U.S. indie producer Ted Hope who kicked off ECAM Forum's masterclass sessions with standout industry voices in 2024, Bonello will discuss his visionary work on June 12 at the Cineteca Madrid. Concurrently, the screening of three of his defining works –Cannes official entries 'Tiresia' (2003), 'House of Tolerance' (2011) and Directors' Fortnight's 'Zombi Child' (2019) – will serve as entry points to his cinematic journey. More from Variety Spain's ECAM Forum and Conecta Fiction & Entertainment Unite for International Collaboration How Saint Laurent Recreated an Iconic 1966 Tuxedo Jacket for Paolo Sorrentino's 'Parthenope' Bertrand Bonello on AI, Freaky Change and How His Next Project Will Be a Totally Different Beast: 'Now I Have to Turn the Page and Be Somewhere Else' The Bonello tribute is organized by ECAM Forum – the new industry event spearheaded by Madrid's prestigious film school ECAM – together with Cineteca Madrid and Filmadrid Festival, in conjunction with collection agent DAMA and the Institut Français in Spain. 'Bertrand Bonello is not only one of the most important contemporary filmmakers, but also one the directors who reflects with the greatest lucidity on the value of creating images today and on the power and prospects of cinema in this paralyzing present,' said ECAM Forum coordinator Alberto Valverde. 'It is an absolute luxury to host him at ECAM Forum, to be able to review three of his fundamental works, and to have him deliver a masterclass for this second edition,'. Nuria Cubas, director of Filmadrid added: 'We are very happy to begin this collaboration with ECAM Forum and to be able to bring back the Spotlight section, which allows us to delve deeper into the filmographies of filmmakers who are so relevant to the arthouse cinema scene. We are proud that Bertrand Bonello joins the list of names to whom we have dedicated a Spotlight in previous editions, such as Pietro Marcello, Lav Diaz, Dan Sallitt, and Deborah Stratman.' The Bonello masterclass will be one of the highlights of EFAM Forum's second edition next to the centrepiece pitching sessions Films to Come for features in development looking for international co-financiers and co-producers, and Last Push, for works in progress looking for distribution, sales and festivals. To highlight ECAM Forum as the new go-to co-production market merging Spain's wealth of talents with key international players, this year's curated slate of 15 Films to Come and 8 Last Push projects will be unveiled May 19 at Cannes' Marché du Film. The launch at the Spanish Pavilion will be attended by Ignasi Camós, head of Spanish film agency ICAA, as well as representatives from the Community of Madrid and Madrid City Council. Novelties this year include the opening of the curated pitching slate to international projects, and a collaboration with the established Conecta Fiction & Entertainment co-production market to be held June 16-19 in Cuenca, Spain, a few days after ECAM Forum. Through the Conecta partnership, a strong delegation of French professionals will attend the relaxed medium-sized industry confab in Madrid, which hosted 250+ delegates in 2024, from Goodfellas, MK2, Films Boutique sales reps to Berlinale, Rotterdam and Series Mania programmers. Stellar talent which formed part of the first cohort of ECAM Forum pitchers who ended up world premiering their works at A-list festivals over the last eight months or so include Denise Fernandes ('Hanami'), Belén Funes ('The Exiles'), Ivan Castiñeiras Gallego ('Gods of Stones') and Lois Patiño ('Ariel'). Best of Variety New Movies Out Now in Theaters: What to See This Week Emmy Predictions: Talk/Scripted Variety Series - The Variety Categories Are Still a Mess; Netflix, Dropout, and 'Hot Ones' Stir Up Buzz Oscars Predictions 2026: 'Sinners' Becomes Early Contender Ahead of Cannes Film Festival
Business Insider
6 days ago
- Business
- Business Insider
Guardant Health (GH) Receives a Buy from Craig-Hallum
Craig-Hallum analyst William Bonello maintained a Buy rating on Guardant Health (GH – Research Report) today. The company's shares opened today at $38.45. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bonello is a 4-star analyst with an average return of 8.3% and a 47.27% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Guardant Health, Veracyte, and GeneDx Holdings. Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $60.00, representing a 56.05% upside. In a report released on May 16, Bank of America Securities also maintained a Buy rating on the stock with a $60.00 price target. GH market cap is currently $4.73B and has a P/E ratio of -11.41. Based on the recent corporate insider activity of 149 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year. Earlier this month, Tariq Musa, a Director at GH sold 116.00 shares for a total of $4,644.64.
Yahoo
24-04-2025
- Yahoo
Delaware police identify Clayton man killed after running stop sign
A 73-year-old man killed after he ran a stop sign near Clayton has been identified by Delaware State Police as Joseph Bonello. Bonello, of the Clayton area, was driving a Jeep Compass north on Alley Mill Road west of Clayton about 12:05 p.m. on April 22. As he approached Clayton Delaney Road, police said, he "rolled through" the stop sign at the intersection and his Jeep was struck by a Chevrolet Silverado. READ MORE: Companies continue to consider reincorporation. Does this mean trouble for Delaware? The Silverado's driver, a 40-year-old Clayton-area man, and his two passengers were taken to an area hospital, where they were treated for minor injuries. They were later released. Bonello was also taken to an area hospital, where he was pronounced dead. Anyone who witnessed the crash or has relevant information should contact investigators at (302) 365-8484. Information may also be provided by sending a private Facebook message to the Delaware State Police or contacting Delaware Crime Stoppers at (800) 847-3333. Send tips or story ideas to Esteban Parra at (302) 324-2299 or eparra@ This article originally appeared on Delaware News Journal: Delaware State Police ID Clayton man killed after running stop sign
USA Today
02-03-2025
- Health
- USA Today
These discounted versions of popular weight-loss drugs are going away: What to know
These discounted versions of popular weight-loss drugs are going away: What to know Show Caption Hide Caption Will Ozempic, Wegovy be affordable in the near future? Could the high cost of hugely popular weight loss drugs Ozempic and Wegovy be coming down in the near future? Cheddar Many Americans have turned to compounding pharmacies to get popular weight-loss drugs due to lack of availability or expensive retail price tags. But this option will soon close for consumers. The federal government allows compounding pharmacies to sell copies of drugs when the medications are in short supply. Yet federal regulators recently declared the blockbuster weight-loss drugs Wegovy and Zepbound are no longer in shortage. That means consumers who use telehealth companies or medical spas to get less expensive, compounded versions will need to get their medications elsewhere. That has panicked consumers such as Amanda Bonello, a Marion, Iowa, mother of three, who worries the supply cutoff will force her to buy the brand-name version of a drug she can't afford. She takes a compounded version of tirzepatide, Eli Lilly's drug sold under the name Mounjaro to treat diabetes and Zepbound for weight loss. The average retail price for Zepbound is nearly $1,300, according to GoodRx, a prescription drug discount provider. "It leaves me up a creek without a paddle," Bonello said. "It feels like we're all on an island and Big Pharma has the only food source, and they're letting everyone who can't afford it starve." Industry groups that represent compounding pharmacies and suppliers have sued to continue selling these drugs. And patients have started an online petition to extend the time in which they can use compounded GLP-1, or glucagon-like peptide-1, medications. Alternatively, the petition requests the Food and Drug Administration authorize generic versions or encourage drugmakers to lower retail prices. The petition also seeks to compel health insurers to cover these drugs. What's status of compounded Wegovy and Zepbound? Compounding suppliers and pharmacies will soon no longer be allowed to make and sell weight-loss drugs for the mass market. The federal government has authorized a transition period that's already partly closed for compounded versions of Zepbound and Mounjaro. Consumers will have a bit longer to get compounded semaglutide, which is sold under the brands Wegovy for weight loss and Ozempic for diabetes. In December, the FDA declared Eli Lilly's tirzepatide was no longer in short supply. The FDA said pharmacies had until Feb. 18 to discontinue compounding, distributing or dispensing tirzepatide. Suppliers that produce batches of the drug and sell to others have until March 19 to cease distribution. The industry trade group Outsourcing Facilities Association sued the FDA in U.S. District Court in Texas and filed a motion seeking to delay such enforcement. In a legal response to the industry trade group's motion, the FDA urged the court to reject the group's request. The agency argues rejecting the request would "maximize patient safety" and adhere to Congress' intent to incentivize drug development while allowing compounding during temporary drug shortages. Last month, the FDA said the shortage of shortage of Novo Nordisk's semaglutide is over. Pharmacies must cease selling compounded semaglutide by April 22. Facilities that supply compounded semaglutide injections must cease distributing the drug by May 22. I take compounded weight-loss drugs. What will my doctor or pharmacist tell me? Pharmacists who supply compounded weight-loss and diabetes drugs already are discussing the situation with customers. Some aren't refilling prescriptions. Others don't want to start new customers on the compounded medications because they'll soon need to switch to brand-name medications. Within a year of discontinuing semaglutide, a group of 327 patients in the U.S., Europe and Japan regained two-thirds of weight lost while on the medication, one study found. The study said also said the patients were less healthy than they were while on the medication. Jennifer Burch, who runs an independent compounding pharmacy in North Carolina, said she informs all her patients about how compounded drugs are available only when a brand name is on the FDA's shortage list. She fields questions from people who are interested in starting on compounded tirzepatide. With the drug shortage ending, she advises patients to not start taking compounded drugs if they won't be able to access or afford the brand-name drugs. "We try to make sure they know that up front," said Burch, who is president of the Pharmacy Compounding Foundation. "We don't want to pull the rug out from under them." Burch added some patients want doctors to write longer-term prescriptions so they can stockpile the compounded medication for up to one year. But doctors are reluctant to do that because they must monitor patients weight loss and overall health while on the medication, she said. "I had a provider yesterday who said, 'I'm really scared to write 12 months for a patient. They'll come back to me and they'll weigh 100 pounds. That's not really what I want,'" Burch said. The industry group Alliance for Pharmacy Compounding urged the FDA to approve the transition period for people taking compounded weight-loss medications to give them time to prepare for such as change, said CEO Scott Brunner. Brunner said patients often must go back to their doctor or telehealth provider and get a new prescription for their weight-loss medications. This transition period gives pharmacies enough time to prepare for the change without abruptly changing patients prescriptions. "This is all about continuation of care, assuring patients don't experience some interruption of therapy," Brunner said. "Abruptly ending these GLP-1 drugs can have potential health consequences." What's being done to make brand name versions of weight-loss drugs more affordable? Most large companies that provide health insurance benefits for workers and private insurance companies cover diabetes drugs such as Ozempic and Mounjaro. But a survey last year by the benefits consultant Mercer said fewer half of large employers covered GLP-1 drugs for obesity. That means consumers often face large bills for drugs that retail for about $1,300 per month, before rebates or discounts. While Congress has scrutinized pharmaceutical companies over the retail price of these medications, drugmakers have rolled out some discounted, direct-to-consumer options. Last week, Eli Lilly slashed the monthly price for lower-dosage vials of Zepbound by $50 for consumers who pay cash via the drugmaker's LillyDirect website. Consumers who buy a month's supply of 2.5-mg vials will now pay $349 and 5-mg vials will cost $499. Lilly also announced higher dosages of 7.5 and 10 mg at monthly prices $599 and $699 respectively. Those higher dosage prices will be discounted to $499 per month for the first fill, as well as refills within 45 days. Meanwhile, drug compounders are still pressing legal challenges to the FDA's decision to declare the weight-loss drug shortages over. The Outsourcing Facilities Association sued the FDA on Monday over its decision to declare Novo Nordisk's Wegovy and Ozempic are no longer in shortage. The industry group earlier sued the agency over declaration that Lilly's tirzepatide was no longer in short supply. In the tirzepatide lawsuit, the OFA filed a motion arguing the FDA's shortage decision was effectively a new rule that requires a more comprehensive regulatory process. A federal judge has not yet ruled on the motion. The FDA said it won't enforce its Feb. 18 deadline for compounding pharmacies to discontinue the drug until the court rules on the motion. After the FDA declared the tirzepatide shortage over, Bonello said she planned to ask her doctor to switch her to compounded semaglutide. Now, she realizes that's not a lasting solution, either. Her workplace insurance plan covers GLP-1 diabetes medications but it doesn't cover weight-loss medications. Although she has elevated blood sugar, she doesn't have diabetes, even though other family members have been diagnosed. Even with Lilly's discounted price of $499 for the higher dosages announced this week, Bonello said she can't afford that amount and still pay daily living expenses. "That's more than my phone bill and car insurance combined," she said.
Yahoo
05-02-2025
- Business
- Yahoo
Consumers, businesses feeling egg price hikes
COLUMBUS, Ohio (WCMH) — Cases of avian influenza, also known as bird flu, are on the rise and egg supplies and prices are ruffling some feathers at businesses and grocery stores in central Ohio. According to the Ohio Department of Agriculture, Ohio has reported the highest number of bird flu cases among commercial poultry operations in the country resulting in a domino effect. If you have sticker shock from egg prices, you're not alone. Shoppers like Zack Burgess are in the same boat. Waffle House adding surcharge for every egg ordered 'The one brand that I get usually is still pretty reasonably priced like $5, $5.50, but another brand that I usually get, it went from about $6 is now $11,' Burgess said. Three Bites Bakery owner Isabella Bonello said she's also feeling the effects. 'Two weeks ago, I bought a case of eggs, it's about 15 dozen eggs, for about $95,' Bonello said. 'Then when I went to place the same order yesterday, they were up to about $147.' Bird flu continues to impact egg-laying flocks, forcing suppliers to cut production, and causing shortages and increased prices. Bonello said that as a small business owner, she's scared. State employees in Ohio ordered to return to the office full time 'It raises your bottom line for sure,' Bonello said. 'So an already struggling food business is going to struggle even more because the profit margins are so much smaller.' Bonello said she uses eggs in almost everything she makes. 'I think a lot of people lose sight of the fact that if you are feeling an increase of costs when you go to the grocery store, right, what do you think is happening to us?' Bonello said. 'It's no different for us.' According to Bonello, the impact is more noticeable this time around than the last major wave of bird flu a few years ago. 'And we still have to pay our employees,' Bonello said. 'We still have to pay rent. We still have to pay, you know, utilities. All of those things still cost money.' Mediterranean eatery opens new location in Grandview Yard Bonello purchases eggs from a local producer. She said the smaller farms typically aren't hit as hard. 'But to see even those go up and those are probably also just going up because demand is so high,' Bonello said. Bonello said she fears this is just the tip of the iceberg. 'If prices continue to go up in the way that egg prices are going up, the only way we'll be able to stay open is if we pass those expenses on to the customer,' she said. 'It's just the way that buying and selling goods works, unfortunately.' A statement from Jim Chakeres, executive vice president of Ohio Poultry Association reads: 'Ohio's egg, chicken and turkey farmers are committed to caring for their flocks and doing all that is possible to prevent the introduction of highly pathogenic avian influenza (HPAI) on their farms. HPAI is devastating to farmers and the birds they raise. 'Extensive on-farm biosecurity and stringent disease prevention practices in place are effective, but not foolproof, and the migration of wild birds and waterfowl spreading the disease have led to continued cases of bird flu in Ohio's commercial poultry flocks. 'The Ohio Department of Agriculture (ODA) and USDA have been supporting farmers in counties affected by this virus. These farms are working closely with federal and state officials to take necessary precautions and emergency measures to prevent the disease from spreading further. 'It is important to know that both USDA and FDA confirm that HPAI cannot be transmitted through safely handled and thoroughly cooked meat or eggs, and the CDC reinforces the risk of HPAI to public health remains low. 'OPA urges all poultry owners to remain in a heightened state of biosecurity and disease prevention practices, including limiting on-farm visitors and vehicles. We greatly value the support and guidance of USDA and the Ohio Department of Agriculture as we navigate this difficult time.' Meantime a statement from Giant Eagle reads: 'We have been actively exploring all opportunities to limit the impact that rising industry egg costs have on our customers. To best support our customers during this uncertain time, we have made the decision to sell all conventional shelled eggs at or below our cost across all our supermarkets starting this Thursday. Additionally, we are updating our in-store signage to encourage customers to limit their purchases to no more than three egg cartons per transaction to help ensure supply for as many customers as possible. 'While it is difficult for any retailer to predict the impact the avian influenza and other factors will have on egg costs in the coming weeks and months, we believe these actions are necessary to show up for our customers at this important moment.' The Agriculture Department predicts egg prices are going to continue to soar another 20% in 2025. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
